Newcastle upon Tyne Hospital

Running trials

• Recruiting

  A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1

  NCT06667453· Phase 2· PepGen Inc· Source

• Active, not recruiting

  EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

  NCT06923761· Phase 1/2· Grey Wolf Therapeutics· Source

• Active, not recruiting

  An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

  NCT05876754· Phase 3· Servier Affaires Médicales· Source

• Recruiting

  DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.

  NCT07717437· Maastricht University Medical Center· Source

• Recruiting

  Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

  NCT04068597· Phase 1/2· CellCentric Ltd.· Source

• Active, not recruiting

  Zimmer POLAR Persona - TKA (EMEA Study)

  NCT02337244· Zimmer, GmbH· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia1 recruiting
• Liver and biliary tract cancer1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myotonic dystrophy1 recruiting

Closed trials

• Terminated

  A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

  NCT05171075· Phase 3· Anthos Therapeutics, Inc.· Source

• Terminated

  A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

  NCT05171049· Phase 3· Anthos Therapeutics, Inc.· Source

• Completed

  Folic Acid Clinical Trial: Follow up of Children (FACT 4 Child)

  NCT03269110· Ottawa Hospital Research Institute· Source

• Completed

  National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

  NCT02664935· Phase 2· University of Birmingham· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Mitochondrial disease3 works · 0 trials